IlluminOss Medical was issued two new patents related to its internal bone fixation system.
The company is focused on minimally invasive orthopedic fracture repair and now has more than 55 patents in 17 countries. Additional patents are pending related to the IlluminOss System for minimally invasive fixation and broken bone treatment.
Here are five quick facts about the two patents:
• They cover internal bone fixation devices and kits for repairing weakened or fractured bones.
• The patents also cover the methods for internal fixation of the fractured bone.
• Proprietary IlluminOss Systems include a thin-walled PET balloon infused with liquid monomer and inserted into the intramedullary canal.
• Bone forms as an implant when the surgeon activates the visible light with the PET balloon.
• The implant can provide longitudinal strength and rotational stability.
IlluminOss also recently received conditional approval from the FDA to conduct clinical trials in the United States on treatment for impending and pathological fractures in the humerus due to metastatic carcinoma.
"We are confident that our unique approach to fracture repair will be a true game-changer in how orthopedic surgery will be performed around the world and we have made significant strides in the last 12 months towards furthering our place in the market and safeguarding IlluminOss' intellectual property," said President and CEO Robert Rabiner.
The company had a successful trial in Europe and hopes similar results are found from the trials in the United States.